|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating Activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock-based compensation | |||||
| Depreciation | |||||
| Amortization of right of use asset | |||||
| Changes in operating assets and liabilities: | |||||
| Tax receivable | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Accounts payable and accrued expenses | |||||
| Operating lease liability | |||||
| Net cash used in operating activities | |||||
| Investing Activities: | |||||
| Purchase of property and equipment | |||||
| Purchase of short-term investments | |||||
| Net cash used in investing activities | |||||
| Financing Activities: | |||||
| Payments of deferred offering costs | |||||
| Proceeds from exercise of stock options | |||||
| Proceeds from exercise of stock warrants | |||||
| Proceeds from sale of Nexcella common stock | |||||
| Net cash provided by financing activities | |||||
| Effect of foreign currency on cash | |||||
| Net change in cash and cash equivalents | |||||
| Cash and cash equivalents - beginning of year | |||||
| Cash and cash equivalents - end of year | |||||
| Supplemental Disclosures of Cash Flow Information: | |||||
| Establishment of right of use asset and liabilities | |||||
| Purchases of property and equipment included in accounts payable and accrued liabilities | |||||
| Nexcella shares issued for funds previously received | |||||
| Deferred offering costs charged against proceeds from sale of common stock | |||||
| Shares issues in subsidiary absorption | |||||
| Shares issued for vested RSUs | |||||
Loading...